TScan Therapeutics, Inc.TCRXNASDAQ
Loading
Gross Profit Growth Recovery in ProgressRecovering
Percentile Rank58
5Y CAGR-2.2%
Year-over-Year Change
Year-over-year gross profit growth rate
5Y CAGR
-2.2%/yr
Long-term compound
Percentile
P58
Within normal range
vs 5Y Ago
0.9x
Contraction
Streak
1 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q4 2025 | 5.73% |
| Q3 2025 | -43.30% |
| Q2 2025 | 41.69% |
| Q1 2025 | 226.47% |
| Q4 2024 | -36.61% |
| Q3 2024 | 95.71% |
| Q2 2024 | -5.30% |
| Q1 2024 | -90.46% |
| Q4 2023 | 52.59% |
| Q3 2023 | 23.48% |
| Q2 2023 | -53.73% |
| Q1 2023 | 322.28% |
| Q4 2022 | -52.10% |
| Q3 2022 | 132.22% |
| Q2 2022 | 10.55% |
| Q1 2022 | -19.63% |
| Q4 2021 | 17.30% |
| Q3 2021 | -48.30% |
| Q2 2021 | -49.72% |
| Q1 2021 | -2.77% |
| Q4 2020 | 6.41% |
| Q3 2020 | -22.68% |
| Q2 2020 | -4.75% |
| Q1 2020 | 0.00% |
| Q4 2019 | 0.00% |